Fans of Circassia (CIR) will have pinned much of their hope on the company's potentially game-changing allergy products, the most advanced of which should find regulatory approval in the next 12-18 months.
IC TIP:
Buy
at
277p
But thanks to the acquisition of Prosonix in June, Circassia is proving it can take on big pharma in the well-established respiratory field too. European regulators gave the green light to the group's new generic asthma inhaler this week, making it a direct competitor with drugs giant GlaxoSmithKline (GSK) which has a similar product on the market.
